A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-[(1S)-1-(1-methyl-
已经发现了一系列新型的3-
喹啉羧酰胺,并将其优化为共济失调毛细血管扩张突变(ATM)激酶的选择性
抑制剂。从适度强力的H
TS命中(4),我们确定了诸如6- [6-(甲氧基甲基)-3-
吡啶基] -4-[((1 R)-1-(tetrahydro-2 H -pyran-4-酰基)乙基]
氨基} -3-
喹啉甲酰胺(72)和7-
氟-6- [6-(甲氧基甲基)
吡啶-3-基] -4-[((1 S)-1-(1-甲基-1)H-
吡唑-3-基)乙基]
氨基}
喹啉-3-羧酰胺(74)作为有效的和高度选择性的ATM
抑制剂,具有适合口服的整体A
DME特性。72和74构成探测体内ATM抑制作用的出色口头工具。在疾病相关模型中观察到与DSB诱导剂
伊立替康联用的疗效。